Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.18 million shs19.38 million shs
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$7.77
-2.8%
$7.67
$6.07
$16.98
$600.23M1.41.19 million shs1.00 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$9.15
-2.9%
$8.95
$6.50
$18.98
$968.89M0.8885,669 shs437,295 shs
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$1.41
-2.1%
$1.32
$1.01
$5.44
$101.45M1.591.44 million shs412,643 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.08%+54.00%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
+0.58%-3.41%+6.36%+15.16%-46.00%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.95%-0.66%+8.16%+19.75%-39.01%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
+3.60%+5.11%-4.00%+11.63%-66.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
4.6064 of 5 stars
3.13.00.03.91.81.73.1
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.3406 of 5 stars
4.41.00.00.01.61.70.0
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
2.3466 of 5 stars
3.32.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.20
Hold$11.6049.29% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.89
Moderate Buy$21.29132.63% Upside
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
2.50
Moderate Buy$8.37493.38% Upside

Current Analyst Ratings Breakdown

Latest OMI, FNA, ZNTL, and RCUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.00
5/15/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
5/15/2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/9/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.00
5/8/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.00
4/23/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$10.70B0.06$8.83 per share0.88$7.33 per share1.06
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.76N/AN/A$5.30 per share1.73
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$67.43M1.50N/AN/A$4.73 per share0.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-$362.69M-$4.75N/A4.410.35-3.41%17.09%2.47%8/1/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$165.84M-$3.13N/AN/AN/AN/A-65.48%-51.05%8/8/2025 (Estimated)

Latest OMI, FNA, ZNTL, and RCUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.14N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$0.56N/AN/AN/AN/AN/A
8/1/2025Q2 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.27N/AN/AN/A$2.73 billionN/A
5/14/2025Q1 2025
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
-$0.67-$0.67N/A-$0.67N/AN/A
5/10/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03N/AN/AN/A
5/8/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03-$0.32$2.66 billion$2.63 billion
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.32
1.13
0.41
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.09
5.37
5.37
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A
6.94
6.94

Institutional Ownership

CompanyInstitutional Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
98.04%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.69%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
23,20077.25 million74.40 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million95.72 millionOptionable
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
16071.95 million70.59 millionOptionable

Recent News About These Companies

Zentalis shares insights on cancer research at AACR
Zentalis presents updated clinical data on azenosertib as SGO 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Paragon 28 stock logo

Paragon 28 NYSE:FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Owens & Minor stock logo

Owens & Minor NYSE:OMI

$7.77 -0.22 (-2.75%)
Closing price 03:59 PM Eastern
Extended Trading
$7.76 0.00 (-0.06%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$9.15 -0.27 (-2.87%)
Closing price 03:59 PM Eastern
Extended Trading
$9.28 +0.13 (+1.43%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zentalis Pharmaceuticals stock logo

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.41 -0.03 (-2.08%)
Closing price 04:00 PM Eastern
Extended Trading
$1.40 0.00 (-0.35%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.